Voyager Therapeutics ROE 2014-2022 | VYGR

Current and historical return on equity (ROE) values for Voyager Therapeutics (VYGR) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Voyager Therapeutics ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-03-31 $-0.07B $0.08B -75.88%
2021-12-31 $-0.07B $0.10B -66.20%
2021-09-30 $-0.09B $0.09B -76.23%
2021-06-30 $0.02B $0.11B 12.70%
2021-03-31 $0.04B $0.14B 29.27%
2020-12-31 $0.04B $0.15B 31.03%
2020-09-30 $0.04B $0.17B 37.83%
2020-06-30 $-0.06B $0.08B -66.85%
2020-03-31 $-0.04B $0.08B -40.39%
2019-12-31 $-0.04B $0.10B -41.22%
2019-09-30 $-0.05B $0.11B -57.91%
2019-06-30 $-0.06B $0.12B -71.30%
2019-03-31 $-0.10B $0.10B -130.17%
2018-12-31 $-0.09B $0.05B -121.92%
2018-09-30 $-0.08B $0.07B -82.11%
2018-06-30 $-0.08B $0.08B -81.20%
2018-03-31 $-0.07B $0.10B -70.14%
2017-12-31 $-0.07B $0.13B -63.53%
2017-09-30 $-0.07B $0.09B -65.92%
2017-06-30 $-0.06B $0.11B -46.78%
2017-03-31 $-0.05B $0.12B -35.46%
2016-12-31 $-0.04B $0.14B -26.45%
2016-09-30 $-0.03B $0.15B -21.32%
2016-06-30 $-0.03B $0.16B -21.66%
2016-03-31 $-0.03B $0.16B -27.59%
2015-12-31 $-0.04B $0.17B -57.56%
2015-09-30 $-0.04B $0.10B -135.92%
2015-06-30 $-0.03B $0.00B -12800.00%
2015-03-31 $-0.03B $0.00B -12000.00%
2014-12-31 $-0.02B $0.00B -6800.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.227B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00